KJIM :: Korean Journal of Internal Medicine

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen

Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

Changbin Wang, Ran Zhang, Xiaorong Sun, Ligang Xing

memo - Magazine of European Medical Oncology.2024; 17(2): 100. CrossRef

Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma

Yangui Lin, Dan Li, Hongliang Hui, Haoran Miao, Min Luo, Bhaskar Roy, Binbin Chen, Wei Zhang, Di Shao, Di Ma, Yanbing Jie, Fan Qiu, Huaming Li, Bo Jiang

Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy

James Yu, Yuan Du, Tarek Mekhail, Mark A. Socinski, Chung-Che Chang

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

Dan Li, Li Ding, Wenwen Ran, Yan Huang, Guangqi Li, Chengqin Wang, Yujing Xiao, Xiaonan Wang, Dongliang Lin, Xiaoming Xing

Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma

Yanqing Chen, Yang Yang, Longbai Ma, Huiyuan Zhu, Tienan Feng, Sen Jiang, Youyong Wei, Tingting Wang, Xiwen Sun

European Journal of Radiology.2019; 112: 44. CrossRef

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea

Hope S. Rugo, Jack A. Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek, Linda Bosserman

Breast Cancer Research and Treatment.2019; 175(1): 5. CrossRef

Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse

Zsolt Mervai, Krisztina Egedi, Ilona Kovalszky, Kornélia Baghy

EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients

Yong Won Choi, So Yeon Jeon, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Young Wha Koh, Jae Ho Han, Seung Soo Sheen

American Journal of Clinical Oncology.2018; 41(4): 385. CrossRef

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine.2017; 32(3): 422. CrossRef

Coexistence of an <i>EGFR</i> Mutation and an <i>ALK</i> Rearrangement in a Patient with Lung Adenocarcinoma: a Case Report

Min Ah Kim, Jin-Hyoung Kang, In-Ho Kim, Tae-Jung Kim, Seung Joon Kim, Sook Whan Sung, Sol Mi Huo

The Korean Journal of Medicine.2016; 90(1): 72. CrossRef

Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma

Eun Young Kim, Eun Na Cho, Heae Surng Park, Arum Kim, Ji Young Hong, Seri Lim, Jong Pil Youn, Seung Yong Hwang, Yoon Soo Chang

CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment

Jeremy L Warner, Lucy Wang, William Pao, Jeffrey A Sosman, Ravi V Atreya, Pam Carney, Mia A Levy

Journal of the American Medical Informatics Association.2016; 23(4): 692. CrossRef

Epidemiology of Lung Cancer in Korea: Recent Trends

Tuberculosis and Respiratory Diseases.2016; 79(2): 58. CrossRef

Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

Aaron M. Chapman, Kathie Y. Sun, Peter Ruestow, Dallas M. Cowan, Amy K. Madl

Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways

Vítor Sousa, Bruno Bastos, Maria Silva, Ana Maria Alarcão, Lina Carvalho

Revista Portuguesa de Pneumologia (English Edition).2015; 21(5): 259. CrossRef

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

Seyyed Mortaza Haghgoo, Abdolamir Allameh, Esmaeil Mortaz, Johan Garssen, Gert Folkerts, Peter J. Barnes, Ian M. Adcock

European Journal of Pharmacology.2015; 754: 82. CrossRef

Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients

Bibhu Ranjan Das, Sangeet Bhaumik, Firoz Ahmad, Aziz Mandsaurwala, Heena Satam

Pathology & Oncology Research.2015; 21(3): 675. CrossRef

The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer

Acta Pharmacologica Sinica.2015; 36(3): 291. CrossRef

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements

Sojung Park, Tai Sun Park, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Jung-Shin Lee, Woo Sung Kim, Joon Seon Song, Jae Cheol Lee

Analysis of an EGFR mutation by PNA clamping method in lung carcinoid tumors

KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression

Eun Young Kim, Arum Kim, Se Kyu Kim, Hyung Jung Kim, Joon Chang, Chul Min Ahn, Jae Seok Lee, Hyo Sup Shim, Yoon Soo Chang

Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma

Jui-Sheng Hsu, Ming-Shyan Huang, Chiao-Yun Chen, Gin-Chung Liu, Ta-Chih Liu, Inn-Wen Chong, Shah-Hwa Chou, Chih-Jen Yang

Journal of Thoracic Imaging.2014; 29(6): 357. CrossRef

WITHDRAWN: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways

Vítor Sousa, Bruno Bastos, Maria Silva, Ana Maria Alarcão, Lina Carvalho

Revista Portuguesa de Pneumologia.2014;[Epub] CrossRef

Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population

NAJLA FAKHRUDDIN, RAMI MAHFOUZ, FADI FARHAT, ARAFAT TFAYLI, RABAB ABDELKHALIK, MARK JABBOUR, LAMIS YEHIA, ZIYAD MAHFOUD, GHAZI ZAATARI

EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features

Yuanyang Lai, Zhipei Zhang, Jianzhong Li, Dong Sun, Yong'an Zhou, Tao Jiang, Yong Han, Lijun Huang, Yifang Zhu, Xiaofei Li, Xiaolong Yan

International Journal of Molecular Sciences.2013; 14(12): 24549. CrossRef

Identification of Uncommon PIK3CA Mutations in Lung Cancer by Using Pyrosequencing

Verena Schildgen, Jessica Lüsebrink, Jan D. Appel, Christine Wübben, Walburga Engel-Riedel, Corinna Ludwig, Erich Stoelben, Oliver Schildgen, Michael Brockmann

Diagnostic Molecular Pathology.2013; 22(1): 22. CrossRef

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Seung Tae Kim, Jae Sook Sung, Uk Hyun Jo, Kyong Hwa Park, Sang Won Shin, Yeul Hong Kim

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer

Kit W. Tam, Wei Zhang, Junichi Soh, Victor Stastny, Min Chen, Han Sun, Kelsie Thu, Jonathan J. Rios, Chenchen Yang, Crystal N. Marconett, Suhaida. A. Selamat, Ite A. Laird-Offringa, Ayumu Taguchi, Samir Hanash, David Shames, Xiaotu Ma, Michael Q. Zhang, W

Journal of Thoracic Oncology.2013; 8(11): 1378. CrossRef

Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?

Seung Tae Kim, Hae-Yun Jung, Jae Sook Sung, Uk Hyun Jo, Tomoaki Tanaka, Koichi Hagiwara, Kyong Hwa Park, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim

American Journal of Clinical Oncology.2013; 36(1): 57. CrossRef

Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Hui Zhang, Deruo Liu, Shanqing Li, Yongqing Zheng, Xinjie Yang, Xi Li, Quan Zhang, Na Qin, Jialin Lu, Lifen Ren-Heidenreich, Huiyi Yang, Yuhua Wu, Xinyong Zhang, Jingying Nong, Yifen Sun, Shucai Zhang

The Journal of Molecular Diagnostics.2013; 15(6): 819. CrossRef

EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS‐TBNA

Yeh Rim Kang, Hye Yun Park, Kyeongman Jeon, Won‐Jung Koh, Gee Young Suh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Yoon‐La Choi, Joungho Han, Sang‐Won Um

Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients

Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim

The Ewha Medical Journal.2013; 36(1): 51. CrossRef

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors

Ruth Sardinha, Teresa Hernández, Susana Fraile, Francesc Tresserra, August Vidal, Maria Carmén Gómez, Aurora Astudillo, Nieves Hernández, Javier Saenz de Santamaría, Jaume Ordi, Luis Gonçalves, Rafael Ramos, Carmen Balañá, Enrique de Álava

RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status

Mohd Feroz Mohd Omar, Kosei Ito, Min En Nga, Ross Soo, Bee Keow Peh, Tuty Muliana Ismail, Bhavin Thakkar, Richie Soong, Yoshiaki Ito, Manuel Salto-Tellez

Pathology & Oncology Research.2012; 18(4): 783. CrossRef

Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)

Kwan-Ho Lee, Kye-Young Lee, Young-June Jeon, Maan-Hong Jung, Choonhee Son, Min-Ki Lee, Jeong-Seon Ryu, Sei-Hoon Yang, Jae-Cheol Lee, Young-Chul Kim, Sun-Young Kim

Tuberculosis and Respiratory Diseases.2012; 73(6): 303. CrossRef

EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysis

Jing‐Hua Ren, Wen‐Shan He, Guo‐Li Yan, Min Jin, Kun‐Yu Yang, Gang Wu

Environmental and Molecular Mutagenesis.2012; 53(1): 78. CrossRef

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

Ayodele Ayoola, Amit Barochia, Kiran Belani, Chandra P. Belani

Driver mutations as predictive biomarkers in lung cancer

Current Respiratory Care Reports.2012; 1(1): 21. CrossRef

Establishment and characterization of primary lung cancer cell lines from Chinese population

Chao Zheng, Yi-hua Sun, Xiao-lei Ye, Hai-quan Chen, Hong-bin Ji

Acta Pharmacologica Sinica.2011; 32(3): 385. CrossRef

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung

Epidermal growth factor receptor mutation‐guided treatment for lung cancers: Where are we now?

Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Seung Tae Kim, Yoon Ji Choi, Kyong Hwa Park, Sang Cheul Oh, Jae Hong Seo, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients

Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim

Journal of the Korean Society of Coloproctology.2011; 27(3): 127. CrossRef

Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR

Ronald van Eijk, Jappe Licht, Melanie Schrumpf, Mehrdad Talebian Yazdi, Dina Ruano, Giusi I. Forte, Petra M. Nederlof, Maud Veselic, Klaus F. Rabe, Jouke T. Annema, Vincent Smit, Hans Morreau, Tom van Wezel, Ralf Krahe

Study of the correlation of EGFR and K-RAS gene mutations with its protein expression in non-small cell lung cancer

Huan-ling Luan, Lei-na Sun, Na Dong, Yan Guo, Bao-cun Sun, Zhong-li Zhan

Clinical Oncology and Cancer Research.2010; 7(2): 97. CrossRef

Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene

Yao FONG, Yue‐Shan LIN, Chiou‐Ping LIOU, Chien‐Fen LI, Ching‐Cherng TZENG

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

PAR-4 as a possible new target for pancreatic cancer therapy

Asfar S Azmi, Philip A Philip, Syed F Zafar, Fazlul H Sarkar, Ramzi M Mohammad

Expert Opinion on Therapeutic Targets.2010; 14(6): 611. CrossRef

Chemotherapy for lung cancer: the state of the art in 2009

Expert Review of Anticancer Therapy.2009; 9(10): 1365. CrossRef